HR Execs on the Move


 
PetMeds® is America`s Largest Pet Pharmacy, a publicly traded company (NASDAQ: PETS). We deliver prescription and non-prescription pet meds along with health and nutritional supplements for dogs, cats and horses at substantial savings directly to you. We serve millions of satisfied customers nationwide from one location.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.petmeds.com
  • 420 South Congress Avenue Suite 100
    Delray Beach, FL USA 33445
  • Phone: 800.738.6337

Executives

Name Title Contact Details
Jacqueline Smith
Vice President of People Profile
Dan Pingree
Chief Marketing Officer Profile

Similar Companies

Amt Labs Inc

Amt Labs Inc is a North Salt Lake, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Recruitech International

Recruitech International is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Athenex

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Pharm-RX Chemical Corp

Pharm-RX Chemical Corp is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.